HIKAL
|
The Current P/E Ratio of HIKAL is 74.64.
Share Price | ₹445.0 | Dec 03,2024 |
Market Cap | ₹5,486.9 Cr | |
Earnings-TTM | ₹73.5 Cr | TTM-Consolidated Results |
Price/Earnings | 74.64x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of HIKAL
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹5,486.9 Cr] as on Dec 03,2024
(/) Earnings [ ₹73.5 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 74.64x ]
Thus, for HIKAL , the investors are currently willing to pay 74.64 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of HIKAL !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of HIKAL over the last five years.
Historical PE (Price/Earnings) ratio chart of HIKAL
PE Ratio Performance Analysis for HIKAL
- HIKAL 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 29.14x.
- HIKAL 's operated at median p/e ratio of 30.92x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, HIKAL 's p/e ratio peaked in Mar2024 at 46.91x.
- HIKAL 's p/e ratio hit its five-year low in Mar2020 of 10.22x.
How does HIKAL 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
HIKAL | 73.51 | 74.64 | 5,486.9 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,136.50 | 38.75 | 431,544.0 |
CIPLA LTD | 4,485.22 | 27.63 | 123,920.0 |
DR REDDYS LABORATORIES LTD | 5,406.80 | 18.91 | 102,224.0 |
ZYDUS LIFESCIENCES LTD | 4,298.90 | 22.99 | 98,832.3 |
DIVIS LABORATORIES LTD | 1,836.00 | 89.80 | 164,865.0 |
MANKIND PHARMA LTD | 2,124.86 | 48.25 | 102,527.0 |
TORRENT PHARMACEUTICALS LTD | 1,802.00 | 63.14 | 113,772.0 |
LUPIN LTD | 2,651.94 | 35.81 | 94,953.0 |
AUROBINDO PHARMA LTD | 3,598.83 | 20.44 | 73,544.0 |
ABBOTT INDIA LTD | 1,284.66 | 47.05 | 60,440.8 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs HIKAL 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 18.91x |
Max industry PE | 89.80x |
Median industry PE | 38.75x |
Average industry PE | 44.31x |
You may also like the below Video Courses